相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名:
CMAS Antibody抗体
- 抗体英文名:
CMAS Antibody
- 靶点:
CMAS
- 浓度:
batch dependent
- 应用范围:
IHC, WB
- 适应物种:
Human, Mouse, Rat
- 保质期:
6-12个月
- 抗原来源:
详询
- 目录编号:
orb1260263
- 级别:
科研级
- 库存:
88
- 供应商:
biorbyt
- 标记物:
Unconjugated
- 克隆性:
Polyclonal
- 形态:
Liquid
- 亚型:
IgG
- 免疫原:
Recombinant fusion protein containing a sequence corresponding to amino acids 1-263 of human CMAS (NP_061156.1).
- 规格:
100 ul
产品描述:CMAS Antibody
别名:CMAS, CSS
免疫原:Recombinant fusion protein containing a sequence corresponding to amino acids 1-263 of human CMAS (NP_061156.1).
分子量:Observed: 48kDa
应用注释:WB: 1:500 - 1:2000IHC: 1:50 - 1:200
防腐剂:Liquid
纯化:Affinity 纯化
保存说明:Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
UniProt ID:Q8NFW8
Note:For research use only.



别名:CMAS, CSS
免疫原:Recombinant fusion protein containing a sequence corresponding to amino acids 1-263 of human CMAS (NP_061156.1).
分子量:Observed: 48kDa
应用注释:WB: 1:500 - 1:2000IHC: 1:50 - 1:200
防腐剂:Liquid
纯化:Affinity 纯化
保存说明:Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
UniProt ID:Q8NFW8
Note:For research use only.

Western blot analysis of extracts of various cell lines, using CMAS Antibody (orb1260263) at 1:3000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25 ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 10s.

Immunohistochemistry of paraffin-embedded rat brain using CMAS antibody (orb1260263) at dilution of 1:150 (40x lens).

Immunohistochemistry of paraffin-embedded mouse brain using CMAS antibody (orb1260263) at dilution of 1:150 (40x lens).
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
全生命周期管理 首先我们要确定性能,包括关键质量参数(CQAs)、关键工艺参数(CPPs)和关键材料特性(CMAs)。其次我们应定义设计空间。设计空间是过程的作业范围,它包含了确切的CPP和CMAs范围,以确保CQA能够稳定实现。最后一步是确定所需控制策略,将作业限定在指定的设计空间,同时该控制策略贯穿于整个药物生命周期不断完善的过程中。事实上,QbD的一大亮点在于利用它可在设计空间内进行持续优化,而无需进一步的监管审批。ICHQ8(R2)并没有明确提到分析
技术资料暂无技术资料 索取技术资料
CMAS Antibody抗体,orb1260263,biorbyt
¥10400











